Ozanimod
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Ozanimod
Ozanimod: Known uses and market status in Australia
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Ozanimod, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use found among the candidates is a relation recorded in the knowledge graph, not an approval.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| progressive relapsing multiple sclerosis |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 12271W | Zeposia | Capsule 920 micrograms | Valid |
Safety Considerations
- Contraindications flagged by the knowledge graph (these are model-derived associations, not label text): sleep apnoea syndromes, stroke and cerebrovascular disorders, transient ischaemic attack, vertebrobasilar insufficiency, myocardial infarction, coronary thrombosis, congestive heart failure, sick sinus syndrome, atrioventricular and sinoatrial block, and haemoglobinopathy.
- Drug interactions: 100 interactions were identified. Major-level examples include isometheptene, famotidine, hydrocortisone, triamcinolone, betamethasone, budesonide, bupropion, morphine, clarithromycin, lorcaserin, diethylpropion, dolasetron, palonosetron and phentermine. Moderate-level examples include ranitidine, cimetidine, epinephrine, loperamide, picosulfuric acid and polyethylene glycol with electrolytes.
- Monitoring suggested by the evidence (from the approved relapsing MS use): cardiac effects including first-dose bradycardia, infections, liver enzymes and macular oedema.
Please refer to the TGA-approved Product Information (PI) for authoritative warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.